Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | CCR3 | P51677 | 1/20 | 0.50 |
| ▸ | CCR5 | P51681 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577295 | 0.93 | SMN1; SMN2 (0.53) | KMT2AMEN1CCR5LMNASMN1; SMN2 | |
| SCHEMBL5577288 | 0.89 | CHRM3 (0.56) | KMT2AMEN1SMN1; SMN2CHRM3ACKR3 | |
| SCHEMBL5577693 | 0.88 | CHRM3 (0.54) | KMT2AMEN1CHRM3ACKR3CXCR3 | |
| SCHEMBL5577652 | 0.88 | CCR5 (0.63) | KMT2ACCR3CCR5LMNASMN1; SMN2 | |
| SCHEMBL5577379 | 0.88 | CCR3 (0.53) | CCR3CCR5LMNASMN1; SMN2CHRM3 | |
| SCHEMBL5577572 | 0.88 | CHRM3 (0.54) | KMT2AMEN1CCR3CCR5LMNA | |
| SCHEMBL5577332 | 0.88 | KMT2A (0.48) | KMT2AMEN1CCR5LMNASMN1; SMN2 | |
| SCHEMBL5577427 | 0.88 | ACKR3 (0.55) | KMT2ACHRM3ACKR3POLBCXCR3 | |
| SCHEMBL5577685 | 0.88 | KMT2A (0.46) | KMT2AMEN1CCR5LMNASMN1; SMN2 | |
| SCHEMBL5577402 | 0.87 | MEN1 (0.56) | KMT2AMEN1LMNASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | KMT2A 3527/4885MEN1 748/4885CCR3 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.